Axa
LCTX icon

Axa’s Lineage Cell Therapeutics LCTX Stock Holding History

Axa’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,171,515
Closed -$1.15M – 1268
2019
Q3 		$1.15M Sell
1,171,515
-35,188
-3% -$36.4K ﹤0.01% 965
2019
Q2 		$1.33M Sell
1,206,703
-5,897
-0.5% -$6.8K 0.01% 919
2019
Q1 		$1.59M Hold
1,212,600
– – 0.01% 889
2018
Q4 		$1.11M Sell
1,212,600
-1,189,957
-50% -$1.82M ﹤0.01% 952
2018
Q3 		$4.94M Sell
2,402,557
-228,237
-9% -$479K 0.02% 677
2018
Q2 		$4.74M Buy
2,630,794
+15,866
+0.6% +$31.9K 0.02% 669
2018
Q1 		$6.15M Sell
2,614,928
-12,464
-0.5% -$29.2K 0.02% 591
2017
Q4 		$4.94M Buy
+2,627,392
New +$5.74M 0.02% 655

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
PGP
Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Axa's LCTX Position: Q4 2019 in Review

Axa sold out of Lineage Cell Therapeutics (LCTX) in Q4 2019, closing a stake of 1,171,515 shares — an estimated $1.15M sold.

Axa first reported a position in LCTX in Q4 2017 and held it in 8 quarters. The position peaked at $6.15M in Q1 2018. 108 funds tracked by Wall St. Rank hold LCTX as of Q4 2019.

  • Axa reported no remaining Lineage Cell Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Axa sold 1,171,515 Lineage Cell Therapeutics shares in Q4 2019, an estimated $1.15M.
  • Axa first reported a position in Lineage Cell Therapeutics in Q4 2017 and held it in 8 quarters.
  • Axa's Lineage Cell Therapeutics position peaked at $6.15M in Q1 2018.
  • 108 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q4 2019.

Based on Axa's 13F filing for Q4 2019, filed 18 Feb 2020.